Cullinan Therapeutics, INC Form 4 insider transactions

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of common stock on November 5, 2024, at a weighted average price of $15.64.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of common stock on September 5, 2024, at a weighted average price of $18.09.

Director Mary Thistle acquired 25,743 stock options in Cullinan Therapeutics, Inc. on August 8, 2024.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 8,000 shares of common stock on July 5, 2024, at a weighted average price of $16.33.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, reports acquiring 2,360 shares of common stock through the company's Employee Stock Purchase Plan.

Director Stephen Webster acquired options to purchase 15,806 shares of Cullinan Therapeutics common stock on June 26, 2024.

Director Anthony Rosenberg acquired stock options for 15,806 shares of Cullinan Therapeutics, Inc. on June 26, 2024.

Anne-Marie Martin, a director of Cullinan Therapeutics, acquired stock options for 15,806 shares of common stock on June 26, 2024.

Director David P. Ryan acquires stock options in Cullinan Therapeutics, Inc.

Director Thomas Ebeling exercised stock options and disposed of 18,450 shares of Cullinan Therapeutics (CGEM) on June 10, 2024.

Thomas Ebeling, a director at Cullinan Therapeutics, exercised stock options at prices of $4.3 and $12.73 on May 23, 2024.

Director David D. Meek acquired stock options for 15,618 shares of Cullinan Therapeutics common stock on May 15, 2024.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, exercised stock options and sold shares of common stock on May 6th and 7th, 2024, according to a Form 4 filing with the SEC.

Mary Kay Fenton, CFO of Cullinan Therapeutics, acquired 200,000 stock options on April 29, 2024, according to a Form 4 filing.